EUVIMEDEUVIMED entdecken
Open Access

Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis

Elliot B Tapper iD, Taylor Ryan, Ni Zeng iD, Renee Carter, Jessamine P Winer-Jones iD, Machaon Bonafede iD, Yestle Kim iD

Journal of Comparative Effectiveness Research · 2025

DOI: 10.57264/cer-2024-0223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2025. Verfasst von Elliot B Tapper und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Health Care Costs, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

While only recently approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), many patients with MASH have taken glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of comorbid Type 2 diabetes (T2D) or obesity. This real-world study evaluated treatment patterns, weight loss, healthcare resource utilization, and costs among patients with MASH who initiated GLP-1 RAs. Materials & methods: In a linked electronic health records (Veradigm Network EHR) and claims (Komodo Health) dataset, we identified adults (≥18 years old) with a MASH diagnosis who initiated GLP-1 RA treatment (1 July 2018 to 30 April 2023; index date = date of the first GLP-1 RA claim). Patients with other causes of liver disease or severe complications from MASH were excluded. We required ≥12 months of continuous enrollment pre- (baseline) and post-index (follow-up). Patients were stratified into high and low-dose subgroups. We also identified a comparator cohort of patients who initiated a different class of T2D medication (DPP4, SGLT2, or sulfonylurea) during the same time period. We captured patient characteristics, change in BMI, GLP-1 RA treatment patterns, liver-related events, healthcare utilization, and costs.

Results

We identified 10,316 patients with MASH who initiated a GLP-1 RA (high dose: 2043 [19.8%]; low dose: 8273 [80.2%]) and 2915 who initiated a non-GLP-1 RA T2D medication. GLP-1 RA users were 52.7 years old and 64.3% female. A 5.8% decrease in the percentage of patients with class III obesity was observed among GLP-1 RA users (10.7% among high-dose users; 0.8% among non-users). Overall, 56.1% of GLP-1 RA users discontinued during the 12-month follow-up. Total costs among GLP-1 RA users and non users were $20,912 and $19,019 in the baseline period and $27,586 and $24,917 in the follow-up period, respectively. Medical costs among GLP-1 RA users were $16,293 (baseline) and $16,886 (follow-up). Results were similar for high and low-dose subgroups.

Conclusion

Although some patients with MASH on GLP-1 RAs, particularly those taking higher dosages, may achieve weight loss, outcomes remain suboptimal with frequent discontinuation and high healthcare costs. Real-world GLP-1 RA utilization may be insufficient for resolving chronic metabolic issues, including MASH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Health Care CostsHypoglycemic AgentsFatty LiverHumansFemaleMiddle AgedMaleAdultObesityAgedWeight LossPatient Acceptance of Health Care

Stichwörter der Autor:innen

GLP-1 RAMASHNAFLDhealthcare coststreatment patterns

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Veradigm, Chicago, IL 60654, USA.
  • Madrigal Pharmaceuticals, Inc., West Conshohocken, PA 19428, USA.

ORCID-Profile: Elliot B Tapper, Ni Zeng, Jessamine P Winer-Jones, Machaon Bonafede, Yestle Kim

Zitieren

APA

Tapper, E. B., Ryan, T., Zeng, N., Carter, R., Winer-Jones, J. P., Bonafede, M., & Kim, Y. (2025). Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0223

Vancouver

Tapper EB, Ryan T, Zeng N, Carter R, Winer-Jones JP, Bonafede M, et al. Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis. Journal of Comparative Effectiveness Research. 2025. doi:10.57264/cer-2024-0223

BibTeX
@article{Tapper2025,
  author = {Tapper, Elliot B and Ryan, Taylor and Zeng, Ni and Carter, Renee and Winer-Jones, Jessamine P and Bonafede, Machaon and Kim, Yestle},
  title = {Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  doi = {10.57264/cer-2024-0223}
}
Kostenlos starten →